While sales reps have been the target of many rounds of layoffs recently, Allos Therapeutics has taken a different approach with its announced layoffs. The Westminster, CO-based biotech is laying off 25 researchers and administrative workers--or 13 percent of its staff--as it focuses on sales, particularly of its cancer drug Folotyn.
For now, the company will scale back on its drug research and additional Folotyn clinical trials. Allos saw a 27 percent increase in Folotyn's fourth quarter sales revenue versus the previous quarter; it's looking for a partner for its international marketing of the drug.
- get the Allos release
- read the Denver Business Journal article